These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30905487)

  • 41. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
    Rodríguez-Baño J; Gutiérrez-Gutiérrez B; Machuca I; Pascual A
    Clin Microbiol Rev; 2018 Apr; 31(2):. PubMed ID: 29444952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
    Lee YR; Baker NT
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Germicidal Activity against Carbapenem/Colistin-Resistant Enterobacteriaceae Using a Quantitative Carrier Test Method.
    Kanamori H; Rutala WA; Gergen MF; Sickbert-Bennett EE; Weber DJ
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
    Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carbapenemase-Producing Enterobacteriaceae and Nonfermentative Bacteria, the Philippines, 2013-2016.
    Velasco JM; Valderama MT; Peacock T; Warawadee N; Nogrado K; Navarro FC; Chua D; Apichai S; Sirigade R; Macareo LR; Swierczewski B
    Emerg Infect Dis; 2017 Sep; 23(9):1597-1598. PubMed ID: 28820383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
    Shah PG; Shah SR
    J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies.
    Giacobbe DR; Maraolo AE; Viscoli C
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1707-1709. PubMed ID: 28528405
    [No Abstract]   [Full Text] [Related]  

  • 48. Prevalence of Invasive Infections Due to Carbapenem-Resistant Enterobacteriaceae among Adult Patients in U.S. Hospitals.
    Lodise T; Ye MJ; Zhao Q
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children.
    Chiotos K; Tamma PD; Flett KB; Naumann M; Karandikar MV; Bilker WB; Zaoutis T; Han JH
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis.
    Ni W; Han Y; Liu J; Wei C; Zhao J; Cui J; Wang R; Liu Y
    Medicine (Baltimore); 2016 Mar; 95(11):e3126. PubMed ID: 26986165
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
    Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
    Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sparing carbapenem usage.
    Wilson APR
    J Antimicrob Chemother; 2017 Sep; 72(9):2410-2417. PubMed ID: 28637307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.
    Neuner EA; Gallagher JC
    Virulence; 2017 May; 8(4):440-452. PubMed ID: 27589330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination therapy for carbapenem-resistant Gram-negative bacteria.
    Paul M; Carmeli Y; Durante-Mangoni E; Mouton JW; Tacconelli E; Theuretzbacher U; Mussini C; Leibovici L
    J Antimicrob Chemother; 2014 Sep; 69(9):2305-9. PubMed ID: 24872346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of Infections by OXA-48-Producing Enterobacteriaceae.
    Stewart A; Harris P; Henderson A; Paterson D
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
    Bassetti M; Giacobbe DR; Patel N; Tillotson G; Massey J
    Adv Ther; 2019 Jul; 36(7):1771-1777. PubMed ID: 31098989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transcriptome-based design of antisense inhibitors potentiates carbapenem efficacy in CRE
    Aunins TR; Erickson KE; Chatterjee A
    Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30699-30709. PubMed ID: 33199638
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct determination of carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa from positive blood cultures using laser scattering technology.
    Idelevich EA; Hoy M; Knaack D; Görlich D; Peters G; Borowski M; Becker K
    Int J Antimicrob Agents; 2018 Feb; 51(2):221-226. PubMed ID: 29111432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of carbapenem resistance using phenotypic and genotypic techniques in Enterobacteriaceae isolates.
    Sahin K; Tekin A; Ozdas S; Akin D; Yapislar H; Dilek AR; Sonmez E
    Ann Clin Microbiol Antimicrob; 2015 Oct; 14():44. PubMed ID: 26444537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.